Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis.

Nomoto H, Takahashi Y, Takano Y, Yokoyama H, Tsuchida K, Nagai S, Miya A, Kameda H, Cho KY, Nakamura A, Atsumi T

Pharmaceutics20 Aug 2023Cited by 9 (Europe PMC)

PMID37631377PMCIDPMC10459529DOI10.3390/pharmaceutics15082163PepBankPUB-37631377

Summary

Non-alcoholic fatty liver disease (NAFLD) is an important common comorbidity in individuals with type 2 diabetes (T2DM). Although some glucagon-like peptide-1 receptor agonists (GLP-1RAs) have beneficial effects on NAFLD, the efficacy of once-weekly semaglutide has not been established. This was a subanalysis of the SWITCH-SEMA 1 study, a multicenter, prospective, randomized, parallel-group trial comparing switching from liraglutide or dulaglutide to once-weekly semaglutide in subjects with T2DM (SWITCH) versus continuing current GLP-1RAs (Continue) for 24 weeks. This subanalysis consisted of participants who were suspected to have NAFLD [fatty liver index (FLI) ≥ 30]. In total, 58 participants met the criteria of this subanalysis. There were no statistical differences in baseline characteristics between the SWITCH (n = 31) and Continue groups (n = 27). FLI significantly improved during treatment in the SWITCH group (68.6 to 62.7) but not in the Continue group (71.1 to 72.3) (p < 0.01). The improvement of FLI in the SWITCH group was greater in switching from dulaglutide to semaglutide and significantly correlated with older age (p = 0.016) and lower baseline FLI (p < 0.01). The multiple linear regression analysis revealed that the switch from dulaglutide was associated with an improvement in FLI (p = 0.041). Switching from conventional GLP-1RAs to once-weekly semaglutide might be beneficial for individuals with NAFLD complicated with T2DM.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In T2DM patients with suspected NAFLD, switching to semaglutide improved fatty liver index from 68.6 to 62.7.
In plain wordsIn people with diabetes and suspected fatty liver, switching to semaglutide lowered fatty liver index from baseline.
Peptide
Semaglutide
Outcome
DecreaseFatty liver index change
Study
n = 31
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
FLI
68.6 index
baseline switch group
FLI
62.7 index
follow-up switch group
Source sentences
Summary
FLI significantly improved during treatment in the SWITCH group (68.6 to 62.7) but not in the Continue group (71.1 to 72.3) (p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a subanalysis of the SWITCH-SEMA 1 study, a multicenter, prospective, randomized, parallel-group trial comparing switching from liraglutide or dulaglutide to once-weekly semaglutide in subjects with T2DM (SWITCH) versus continuing current GLP-1RAs (Continue) for 24 weeks.
Summary · context
This subanalysis consisted of participants who were suspected to have NAFLD [fatty liver index (FLI) ≥ 30].
Show in the study text Report a problemFND-3763137701
02HumanObservational studyEfficacy outcome
In T2DM patients with suspected NAFLD who switched to semaglutide, fatty liver index improved more after switching from dulaglutide than after switching from liraglutide.
In plain wordsAmong semaglutide switch recipients with diabetes and suspected fatty liver, prior dulaglutide use was linked to greater improvement than prior liraglutide use.
Peptide
Semaglutide
Outcome
DecreaseFatty liver index by previous drug
Study
n: not reported in source
Comparator
Switching from liraglutide
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The improvement of FLI in the SWITCH group was greater in switching from dulaglutide to semaglutide and significantly correlated with older age (p = 0.016) and lower baseline FLI (p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a subanalysis of the SWITCH-SEMA 1 study, a multicenter, prospective, randomized, parallel-group trial comparing switching from liraglutide or dulaglutide to once-weekly semaglutide in subjects with T2DM (SWITCH) versus continuing current GLP-1RAs (Continue) for 24 weeks.
Summary · context
This subanalysis consisted of participants who were suspected to have NAFLD [fatty liver index (FLI) ≥ 30].
Show in the study text Report a problemFND-3763137704
03HumanObservational studyOther
Among semaglutide switch recipients with suspected NAFLD, older age correlated with greater fatty liver index improvement.
In plain wordsAmong people switching to semaglutide, older age was linked to greater fatty liver index improvement.
Peptide
Semaglutide
Outcome
IncreaseAge association with fatty liver index improvement
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The improvement of FLI in the SWITCH group was greater in switching from dulaglutide to semaglutide and significantly correlated with older age (p = 0.016) and lower baseline FLI (p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a subanalysis of the SWITCH-SEMA 1 study, a multicenter, prospective, randomized, parallel-group trial comparing switching from liraglutide or dulaglutide to once-weekly semaglutide in subjects with T2DM (SWITCH) versus continuing current GLP-1RAs (Continue) for 24 weeks.
Summary · context
This subanalysis consisted of participants who were suspected to have NAFLD [fatty liver index (FLI) ≥ 30].
Show in the study text Report a problemFND-3763137705
04HumanObservational studyOther
Among semaglutide switch recipients with suspected NAFLD, lower baseline fatty liver index correlated with greater improvement.
In plain wordsAmong people switching to semaglutide, lower starting fatty liver index was linked to greater improvement.
Peptide
Semaglutide
Outcome
IncreaseBaseline fatty liver index association
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The improvement of FLI in the SWITCH group was greater in switching from dulaglutide to semaglutide and significantly correlated with older age (p = 0.016) and lower baseline FLI (p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a subanalysis of the SWITCH-SEMA 1 study, a multicenter, prospective, randomized, parallel-group trial comparing switching from liraglutide or dulaglutide to once-weekly semaglutide in subjects with T2DM (SWITCH) versus continuing current GLP-1RAs (Continue) for 24 weeks.
Summary · context
This subanalysis consisted of participants who were suspected to have NAFLD [fatty liver index (FLI) ≥ 30].
Show in the study text Report a problemFND-3763137706
05HumanObservational studyOther
In T2DM patients with suspected NAFLD, switching from dulaglutide to semaglutide was associated with improved fatty liver index in regression analysis.
In plain wordsIn people with diabetes and suspected fatty liver, switching from dulaglutide to semaglutide was linked to improved fatty liver index.
Peptide
Semaglutide
Outcome
DecreaseAdjusted association of previous dulaglutide
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The multiple linear regression analysis revealed that the switch from dulaglutide was associated with an improvement in FLI (p = 0.041).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a subanalysis of the SWITCH-SEMA 1 study, a multicenter, prospective, randomized, parallel-group trial comparing switching from liraglutide or dulaglutide to once-weekly semaglutide in subjects with T2DM (SWITCH) versus continuing current GLP-1RAs (Continue) for 24 weeks.
Summary · context
This subanalysis consisted of participants who were suspected to have NAFLD [fatty liver index (FLI) ≥ 30].
Show in the study text Report a problemFND-3763137707

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

06HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In T2DM patients with suspected NAFLD, continuing pooled liraglutide or dulaglutide did not significantly improve fatty liver index.
In plain wordsIn people with diabetes and suspected fatty liver, pooled liraglutide or dulaglutide continuation did not significantly improve fatty liver index from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePooled continuation fatty liver index
Study
n = 27
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Measurements
FLI
71.1 index
baseline Continue group
FLI
72.3 index
follow-up Continue group
Source sentences
Summary
FLI significantly improved during treatment in the SWITCH group (68.6 to 62.7) but not in the Continue group (71.1 to 72.3) (p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a subanalysis of the SWITCH-SEMA 1 study, a multicenter, prospective, randomized, parallel-group trial comparing switching from liraglutide or dulaglutide to once-weekly semaglutide in subjects with T2DM (SWITCH) versus continuing current GLP-1RAs (Continue) for 24 weeks.
Summary · context
This subanalysis consisted of participants who were suspected to have NAFLD [fatty liver index (FLI) ≥ 30].
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3763137702
07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In T2DM patients with suspected NAFLD, continuing pooled liraglutide or dulaglutide did not significantly improve fatty liver index.
In plain wordsIn people with diabetes and suspected fatty liver, pooled liraglutide or dulaglutide continuation did not significantly improve fatty liver index from baseline.
Peptide
Liraglutide
Outcome
No significant changePooled continuation fatty liver index
Study
n = 27
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Measurements
FLI
71.1 index
baseline Continue group
FLI
72.3 index
follow-up Continue group
Source sentences
Summary
FLI significantly improved during treatment in the SWITCH group (68.6 to 62.7) but not in the Continue group (71.1 to 72.3) (p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a subanalysis of the SWITCH-SEMA 1 study, a multicenter, prospective, randomized, parallel-group trial comparing switching from liraglutide or dulaglutide to once-weekly semaglutide in subjects with T2DM (SWITCH) versus continuing current GLP-1RAs (Continue) for 24 weeks.
Summary · context
This subanalysis consisted of participants who were suspected to have NAFLD [fatty liver index (FLI) ≥ 30].
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3763137703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 3
21 Oct 2026, 18:59 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis.

Summary

Results from this study7

Studies that did not test the peptide alone2

Version history

Subjects

Publication types

Keywords